Compare AbCellera Biologics Inc (ABCL) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $16.55. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | PDBC | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $18.91 |
52-Week Low | $2.78 | $12.90 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
PDBC trades at $16.32, up 2.84% today, with a bullish technical signal despite mixed moving averages and oscillators. The ETF has delivered strong returns, including 37% gains since March 2024, outperforming the S&P 500, though recent commodity momentum has softened. Its structure avoids K-1 tax forms, attracting $4.6 billion in assets as an inflation hedge.
Outlook remains cautiously optimistic given commodity price volatility and geopolitical risks. Opportunities include continued inflation hedging demand, but risks involve oil price declines and unpredictable annual distributions. Recent downgrade to hold reflects near-term caution amid supply disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
